



“IMPROVING THE QUALITY ASSURANCE OF ORGANIC DRUGS PRODUCTION CHALLENGE AND SOLUTIONS”

*Zukaa Mansoura^{*1}, Tanya Sharma², Pankaj Chasta³*

^{*1} Department of Quality Assurance, Mewar University. Gangrar, Chittorgarh, Rajasthan-312901

²⁻³ Faculty of Pharmaceutical Sciences, Mewar University. Gangrar, Chittorgarh, Rajasthan- 312901

Corresponding author: Tanya Sharma

Email: tanyasharma@mewaruniversity.co.in

ABSTRACT :

Background: Natural drugs are widely used in the industry, more than 60% of drugs are their derivatives, so the production of organic drugs has become more and more important; but it also has many challenges, especially quality assurance. For the health of consumers and to uphold regulatory standards, ensuring the safety and efficacy of these drugs is paramount. The objective of this paper is to show the need for a more robust quality assurance system in the organic drug response.

Objective: This research aims to find the influential factors concerning the quality assurance of organic pharmaceuticals and provide some solutions for improving these measures. The study seeks to address the problems which are tried in this industry towards building strong quality assurance frameworks.

Approach: This study utilizes a mixed-methods methodology, integrating experimental analysis and stakeholder-oriented qualitative evaluation. Such an approach gives a holistic perspective on the quality assurance scenario in organic drug manufacturing. To provide practical recommendations for improvement, the research has an extensive analysis of quality control methodologies, regulatory challenges, and sustainable development strategies.

Results: The study outlined challenges faced in the quality assurance of organic drugs, including insufficient regulatory frameworks and a lack of standardized quality control processes. The study reveals key parameters that affect the quality control, including selection of extraction techniques and conditions of production of organic drugs.

Conclusion: This study emphasizes the significance of stringent quality assurance behaviour in organic medicaments, the study aims at improving the quality and safety of the organic pharmaceuticals by addressing the mentioned challenges and forthcoming actionable solutions. These research findings are anticipated to be beneficial to the stakeholders in the pharmaceutical sector that will help bolster practices as well as consumer outcomes.

Keywords: Organic Drugs, Quality Assurance, Regulatory Challenges, Biotechnological Advancements, Analytical Techniques.

1. INTRODUCTION

Background

Organic drugs, particularly those derived from herbal and botanical sources, have played a crucial role in traditional and modern medicine. Their therapeutic potential has been recognized for centuries, with various cultures utilizing plant-based remedies to treat a wide range of diseases. With the increasing shift towards natural and organic products, the demand for organic pharmaceuticals has grown significantly (Yuan et al., 2016). Consumers and healthcare providers are increasingly drawn to organic drugs due to their perceived safety, minimal side effects, and environmental sustainability. However, ensuring the quality, efficacy, and safety of these organic formulations presents substantial challenges (Chaachouay & Zidane, 2024).

Unlike synthetic drugs, which are produced through strictly controlled laboratory processes, organic drugs are dependent on botanical sources, making them vulnerable to variations in environmental conditions, cultivation practices, and processing methods. These factors lead to inconsistencies in the concentration of active ingredients, which can affect the drug's therapeutic efficacy and safety (Wainwright et al., 2022). Additionally, organic drugs are susceptible to microbial contamination, heavy metal accumulation, and other impurities due to the absence of synthetic preservatives and fertilizers. Thus, the implementation of stringent quality assurance (QA) measures is essential to standardize production and ensure product consistency (Li et al., 2021).

1.2. Importance of Quality Assurance in Organic Drug Production

Quality assurance in organic drug production involves a series of regulatory, technological, and procedural measures designed to maintain product consistency, safety, and therapeutic efficacy. Unlike conventional pharmaceutical manufacturing, which follows well-established **Good Manufacturing Practices (GMP)**, the organic drug industry faces unique challenges due to variability in raw materials, extraction processes, and storage conditions.

Some key challenges affecting QA in organic drug production include:

- **Variability in Raw Materials:** The concentration of bioactive compounds in medicinal plants can be influenced by soil composition, climate, harvesting time, and storage conditions. This variability can lead to inconsistent drug potency, requiring advanced analytical techniques to standardize product composition.
- **Microbial and Heavy Metal Contamination:** The absence of synthetic fertilizers and pesticides makes organic raw materials more vulnerable to contamination by bacteria, fungi, and heavy metals. Contaminated drugs pose significant health risks to consumers and can lead to regulatory non-compliance.
- **Lack of Standardized Regulations:** Regulatory guidelines for organic pharmaceuticals vary across countries. While the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) enforce strict pharmaceutical regulations, the certification process for organic drugs remains complex and inconsistent.
- **Complex Production and Storage Processes:** Unlike synthetic drugs, which have a defined chemical structure and standardized production methods, organic drugs require
 - extensive processing, extraction, and purification steps, making quality control more difficult.

To address these challenges, researchers and pharmaceutical manufacturers must implement robust quality assurance protocols, including advanced analytical testing, Good Agricultural and Collection Practices (GACP), and harmonized international regulations.(Adulapuram Aroon et al., 2024)

Regulatory Framework for Organic Drugs

The regulatory landscape for organic pharmaceuticals is multifaceted, with different governing bodies establishing guidelines to ensure product quality and safety. In the United States, the FDA classifies most herbal drugs as dietary supplements rather than pharmaceutical products, subjecting them to different regulatory standards under the Dietary Supplement Health and Education Act (DSHEA). Additionally, the U.S. Department of Agriculture (USDA) regulates organic certification, requiring manufacturers to comply with specific agricultural and processing standards(Thakkar et al., 2020).

In the European Union (EU), organic medicinal products must adhere to both EU organic certification standards and EMA regulations for herbal medicinal products. This dual regulatory requirement ensures that organic drugs meet safety, efficacy, and quality standards while maintaining organic integrity. However, in many developing countries, regulatory frameworks for organic pharmaceuticals remain underdeveloped, leading to widespread issues with product adulteration, mislabelling, and contamination.

Several international organizations are working towards harmonizing quality standards for organic drugs:

- **World Health Organization (WHO):** Provides guidelines for the safety, efficacy, and standardization of herbal medicines.
- **International Organization for Standardization (ISO):** Establishes quality standards for herbal medicines and dietary supplements.
- **United States Pharmacopeia (USP) and European Pharmacopoeia (EP):** Provide monographs detailing quality specifications for medicinal plants and their extracts.

Despite these initiatives, achieving a global quality assurance framework for organic pharmaceuticals remains challenging due to variations in national policies, traditional medicine practices, and technological capabilities(Avigan et al., 2016).

Analytical Techniques for Quality Assurance

Ensuring the quality and consistency of organic drugs requires the implementation of advanced analytical techniques that can detect contaminants, quantify bioactive compounds, and standardize product formulations. Some of the key techniques used in quality control for organic pharmaceuticals include:

- **High-Performance Liquid Chromatography (HPLC):** This method is widely used for the quantification of active ingredients in herbal drugs. HPLC can separate and identify
 - different chemical compounds within a sample, ensuring that each batch of a drug maintains consistent potency.
- **Mass Spectrometry (MS):** Used for detecting contaminants, including heavy metals, pesticides, and microbial toxins, MS enhances the safety evaluation of organic drugs.
- **Nuclear Magnetic Resonance (NMR) Spectroscopy:** Provides detailed structural information about the bioactive compounds in herbal drugs, aiding in their characterization and standardization.
- **Fourier Transform Infrared Spectroscopy (FTIR):** Analyzes functional groups in organic compounds and helps in detecting impurities or adulterants.
- **Microbial Testing:** Given the risk of bacterial and fungal contamination in organic drugs, microbial testing ensures that products meet safety standards before reaching consumers.

These analytical tools play a vital role in maintaining the integrity of organic pharmaceuticals, enabling manufacturers to detect impurities and ensure batch-to-batch consistency(Kumar et al., 2018; Wang et al., 2023).

Sustainable Development in Organic Drug Manufacturing

The increasing demand for organic pharmaceuticals presents an opportunity to integrate sustainable practices into drug production. By adopting eco-friendly cultivation methods, minimizing waste generation, and utilizing renewable resources, pharmaceutical companies can enhance the sustainability of organic drug manufacturing.

Some key sustainable practices in **organic drug production** include:

- **Good Agricultural and Collection Practices (GACP):** Ensuring that medicinal plants are grown under controlled conditions, free from chemical contaminants, and harvested at optimal times to maximize bioactive compound content.
- **Green Extraction Techniques:** Employing eco-friendly extraction methods, such as supercritical fluid extraction and ultrasound-assisted extraction, to minimize solvent use and reduce environmental impact.
- **Circular Economy Models:** Recycling organic waste generated during drug manufacturing to create value-added products, such as herbal teas, nutraceuticals, or bio fertilizers.
- **Energy-Efficient Processing:** Implementing technologies that reduce carbon footprint, such as solar-powered drying techniques and biodegradable packaging for herbal medicines.

Sustainable development in organic drug production not only enhances environmental conservation but also improves the long-term viability of the industry by maintaining product integrity and consumer trust.

Research Significance and Study Objectives

The significance of this research lays in its contribution to the development of robust quality assurance measures for organic drug production. By addressing key challenges and proposing effective solutions, this study aims to:

1. Identify the critical factors affecting the quality assurance of organic pharmaceuticals.
2. Evaluate existing regulatory frameworks and suggest strategies for standardization.
3. Explore the role of advanced analytical techniques in enhancing quality control.
4. Investigate sustainable practices for improving organic drug manufacturing.
5. Propose a framework for global regulatory harmonization to ensure product safety and efficacy.

Through an in-depth analysis of quality control methodologies, regulatory challenges, and sustainable development strategies, this research seeks to provide practical recommendations for enhancing the quality assurance of organic pharmaceuticals.

Aim: Improving the quality assurance of organic drugs production challenge and solutions

Objectives:

- To identify the key challenges that related to Quality assurance of organic drugs.
- To explore innovative solutions and best practices to address these challenges.
- To propose solutions to improve quality control and manufacturing standards.
- To assess consumer awareness and trust in organic pharmaceuticals.

Research Hypotheses

Based on the research objectives, the following hypotheses are formulated to guide the study:

1. **H₀ (Null Hypothesis):** There is no significant impact of quality control measures on the safety and efficacy of organic drug production.
H₁ (Alternative Hypothesis): Implementation of strict quality control measures significantly enhances the safety and efficacy of organic drug production.
2. **H₀:** Advanced analytical techniques (HPLC, MS, and NMR) do not significantly improve the standardization of organic pharmaceuticals.
H₁: The use of advanced analytical techniques significantly improves the consistency, purity, and therapeutic efficacy of organic pharmaceuticals.
3. **H₀:** Variability in cultivation practices and environmental factors does not significantly affect the quality of organic drug formulations.
H₁: Differences in cultivation methods, soil composition, and environmental conditions significantly influence the potency and chemical composition of organic drugs.
4. **H₀:** The implementation of sustainable production methods does not significantly contribute to the quality and market acceptance of organic drugs.
H₁: Sustainable production methods enhance the overall quality, regulatory compliance, and consumer trust in organic pharmaceuticals.
5. **H₀:** Regulatory inconsistencies do not pose a significant challenge to the standardization of organic drug production.
H₁: The lack of harmonized global regulations significantly affects the standardization and international marketability of organic pharmaceuticals.
6. **H₀:** Consumer awareness and trust in organic pharmaceuticals are not significantly influenced by quality assurance measures.

H₁: Higher quality assurance standards and transparency in production significantly improve consumer trust and market demand for organic drugs.

This chapter provides a clear roadmap for addressing the study's objectives and hypotheses, ensuring a structured approach to analyzing quality assurance in organic pharmaceutical production

Material and Methods

List of Chemicals and Equipment Used

Table No. 1: List of chemicals

Sl.No.	Drug/Chemical Name	Company
1	Ethanol	Loba Chemie Pvt .Ltd.
3	Supercritical CO ₂ .	Loba Chemie Pvt. Ltd.
6	Ethanol	Himedia Laboratories Pvt. Ltd.
7	Acetone	Himedia Laboratories Pvt. Ltd.
8	Methanol	Himedia Laboratories Pvt. Ltd.
10	Hydrochloric Acid (HCl)	Himedia Laboratories Pvt. Ltd.
11	Sodium Hydroxide (NaOH)	Himedia Laboratories Pvt. Ltd.
12	Ammonium Acetate	Himedia Laboratories Pvt. Ltd.
	Agar media	CHD Fine chemical Pvt. Ltd.
	Nutrient Broth	CHD Fine chemical Pvt. Ltd
	MacConkey Medium	Sigma Aldrich Pvt. Ltd
	ICP-MS standards for Lead (Pb),	Sigma Aldrich Pvt. Ltd
	Arsenic (As),	Sigma Aldrich Pvt. Ltd
	Cadmium (Cd)	Sigma Aldrich Pvt. Ltd
	Mercury (Hg)	Sigma Aldrich Pvt. Ltd

Table No.2: List of Equipment

Sl.No.	Equipment	Company
1	High-Performance Liquid Chromatography (HPLC)	Thermo Fisher Scientific
2	Gas Chromatography-Mass Spectrometry (GC-MS)	BUNKER
3	Nuclear Magnetic Resonance (NMR)	Citizon (CD4820)

4	Rotatory Evaporator	Buchi (R-100,V-100,1-100,F-105)
5	Electronic balance	Citizon (CY64)
6	UV Spectrophotometer	Shimadzu
7	FT-IR	Broker Lab India(Alpha11)
8	Inductively Coupled Plasma Mass Spectrometry (ICP-MS)	Indosati
9	Ph meter	Indosati (PPS.094)
10	Scanning electron microscope(SEM)	ESEMEDAXXL-30
12	Incubators	Electro lab
13	Autoclave	Indosati (PPS.0933)
14	Colony Counter	Indosati

Apparatus

Beakers (100, 250, 500, 1000 ml), Volumetric flask (10, 100 ml), Measuring cylinder (10, 50 ml), Glass rod, Spatula, Conical flask (100, 500 ml), Funnel, Round bottom flask (500 ml), Pipette, Test tube etc.

Research Design

The study follows a mixed-methods approach incorporating both experimental analysis and stakeholder-based qualitative evaluation to ensure a holistic understanding of quality assurance in organic drug production.

1. Qualitative Analysis

- **Interviews & Focus Group Discussions** with industry experts, regulatory officials, and pharmaceutical manufacturers.
- **Review of Regulatory Documents** to identify inconsistencies and gaps in organic drug certification standards.
- **Market Analysis & Consumer Surveys** to assess public perception and trust in organic pharmaceuticals.

2. Quantitative Analysis

- **Laboratory-Based Experiments** for quality testing of organic drugs.
- **Analytical Chemistry Techniques** such as High-Performance Liquid Chromatography (HPLC), Mass Spectrometry (MS), and Nuclear Magnetic Resonance (NMR).
- **Microbial & Heavy Metal Contamination Testing** to assess safety risks.

1.1 Materials Used

4.2.2. Raw Materials

- **Medicinal Plant Samples:** Collected from certified organic farms following Good Agricultural and Collection Practices (GACP).
- **Organic Drug Formulations:** Extracted from medicinal plants using various solvent-based and eco-friendly extraction methods.

4.2.3 Chemicals and Reagents

- **Solvents for Extraction:** Ethanol, Methanol, Acetone, Supercritical CO₂.
- **Analytical Reagents:** Hydrochloric Acid (HCl), Sodium Hydroxide (NaOH), Ammonium Acetate.
- **Microbiological Media:** Agar, Nutrient Broth, MacConkey Medium for microbial testing.
- **Heavy Metal Testing Kits:** ICP-MS standards for Lead (Pb), Arsenic (As), Cadmium (Cd), Mercury (Hg).

4.3. Methodology

4.3.1 Sample Collection and Processing

1. Collection

- Medicinal plant samples were collected from three different regions to compare quality variations.
- Samples were sourced from certified organic farms and non-certified sources for comparative assessment.

➤ Processing

- Samples were washed, dried in controlled conditions, and ground into a fine powder for extraction.

- Freeze-drying and shade-drying were compared to evaluate phytochemical degradation.

Extraction Methods

Different extraction techniques were used to optimize bioactive compound yield and purity.

➤ Solvent-Based Extraction

- **Ethanol and Methanol** were used as primary solvents.
- Soxhlet extraction and cold maceration techniques were applied.

➤ Eco-Friendly Extraction

- **Supercritical Fluid Extraction (SFE)** using CO₂ to obtain high-purity extracts.
- **Microwave-Assisted Extraction (MAE)** to improve yield and reduce solvent use.

Phytochemical Screening

Phytochemical screening is a crucial analytical process used to detect and identify bioactive compounds present in medicinal plants and herbal formulations. It involves both qualitative and quantitative analyses to ensure the presence and concentration of key phytochemicals, such as alkaloids, flavonoids, tannins, saponins, terpenoids, and phenolics, which contribute to therapeutic efficacy.

Qualitative Analysis is performed using standard chemical tests, such as Mayer's test for alkaloids, Ferric chloride test for phenols, Shinoda test for flavonoids, and Foam test for saponins. These tests help in the preliminary identification of phytoconstituents in plant extracts.

Quantitative Analysis involves advanced analytical techniques, including spectrophotometry, high-performance liquid chromatography (HPLC), gas chromatography-mass spectrometry (GC-MS), and thin-layer chromatography (TLC), to determine the precise concentration of active compounds.

Phytochemical screening is essential for standardizing herbal drugs, ensuring quality control, and validating their pharmacological potential. (Dubale et al., 2023).

1. Qualitative Tests

Alkaloid Test (Mayer's Reagent) for alkaloids.

About 50 mg of solvent – free extract was stirred with little quantity of dilute hydrochloric acid and filtered. The filtrate was tested carefully with various alkaloid reagents as follows.

i. Mayer's Test

To 1 ml of filtrate, two drops of Mayer's reagent was added along the sides of the test tube. If the test is positive, it gives white or creamy precipitate (Kancherla et al., 2019).

ii. Wagner's Test

To 1 ml of the filtrate, a few drops of Wagner's reagent were added along the sides of the test tube. The formation of reddish-brown precipitate confirms the test as positive

iii. Hager's Test

To 1 ml of filtrate, 1 or 2 ml of Hager's reagent was added. A prominent yellow precipitate indicates a positive test

iv. Dragendorff's Test

To 1 ml of filtrate, 1 or 2 ml of Dragendorff's reagent was added. A prominent reddish- brown precipitate indicates a positive test

Tannin Test (Ferric Chloride) for tannins.

Principle:

Tannins are polyphenolic compounds found in plants that react with ferric chloride (FeCl₃) to form a blue-black, green, or brownish-green complex, depending on the type of tannin present.

Materials Required:

- Plant extract (prepared using distilled water or ethanol)
- 1% Ferric chloride (FeCl₃) solution
- Test tubes
- Distilled water

Procedure:

- Prepare the plant extract by dissolving 1 mL of the extract in 5 mL of distilled water.
- Add a few drops of 1% ferric chloride solution to the test solution.
- Observe the colour change.

Observation and Interpretation:

- **Blue-black coloration** → Indicates the presence of hydrolyzable tannins.
- **Greenish-brown coloration** → Indicates the presence of condensed tannins.
- **No colour change** → Indicates the absence of tannins.

Reaction Mechanism:

Tannins have phenolic hydroxyl groups, which react with ferric ions (Fe³⁺) to form a stable complex, leading to the characteristic colour change.

Significance of the Test:

- Helps in the qualitative detection of tannins in herbal extracts.
- Tannins possess antioxidant, antimicrobial, and astringent properties, making them valuable in organic pharmaceuticals.

Flavonoid Test (Shinoda Test) for flavonoids.

Principle:

Flavonoids are polyphenolic compounds that react with **magnesium (Mg) metal** in an acidic medium (hydrochloric acid, HCl), leading to the reduction of flavonoids and the formation of a **reddish-pink or orange coloration**, indicating their presence.

Materials Required:

- Plant extract (prepared in methanol or ethanol)
- Magnesium ribbon or magnesium powder
- Concentrated hydrochloric acid (HCl)
- Test tubes

Procedure:

- Take 1 mL of the plant extract in a test tube.
- Add a small piece of magnesium ribbon (or Mg powder) to the extract.
- Slowly add a few drops of concentrated HCl to the solution.
- Observe the color change.

Observation and Interpretation:

- **Reddish-pink or orange coloration** → Confirms the presence of flavonoids.
- **No colour change** → Indicates the absence of flavonoids.

Reaction Mechanism:

The reaction occurs due to the reduction of flavonoids by nascent hydrogen (H) released from the reaction of magnesium and hydrochloric acid. This reduction leads to a shift in the flavonoids structure, causing the characteristic colour change.

Significance of the Test:

- Flavonoids have antioxidant, anti-inflammatory, and cardio protective properties, making them essential in herbal pharmaceuticals.
- This test helps in the preliminary screening of flavonoids in medicinal plants, aiding in the selection of bioactive plant extracts for further studies.

Quantitative Analysis

Total Phenolic Content (TPC) Determination using Folin-Ciocalteu reagent . A stock solution of extract was prepared. 5 ml of ethanol is added to 0.1 gm of lyophilized extract and then water is added to make the volume 100 ml. 0.4 ml of the stock solution was taken and mixed with 2 ml of 50% Folin-Ciocalteu reagent. The solution mixture was allowed to react for 5 min. The mixture was further reacted with 4 ml of 7.5% Na₂CO₃ and placed in the dark for 1 hr. The absorbance values were compared with the gallic acid (GAE) standard in the range between 10-100 µg/ml. The results obtained were expressed in mg GAE/g extract (Youl et al., 2023)(Moualek et al., 2016).




Figure No 1: Phytochemical Screening

Total Flavonoids Content (TFC) Assay via aluminium chloride colorimetric method.

The aluminium chloride colorimetric method was used for the determination of the total flavonoids content of the sample. For total flavonoids determination, quercetin was used to make the standard calibration curve. Stock quercetin solution was prepared by dissolving 5.0 mg quercetin in 1.0 mL methanol, then the standard solutions of quercetin were prepared by serial dilutions using methanol (1-75 µg/mL). An amount of 0.6 mL diluted standard quercetin solutions or extracts was separately mixed with 0.6 mL of 2% aluminium chloride. After mixing, the solution was incubated for 60 min at room temperature. The absorbance of the

reaction mixtures was measured against a blank at 420 nm wavelength with a Varian UV-Vis spectrophotometer. The concentration of total flavonoids content in the test samples was calculated from the calibration plot ($Y = 0.0162x + 0.0044$, $R^2 = 0.999$) and expressed as mg quercetin equivalent (QE)/g of dried plant material. All the determinations were carried out in triplicate (Chandra et al., 2014)(Shraim et al., 2021).

Quality Control and Standardization

High-Performance Liquid Chromatography (HPLC) was used for standardization of bioactive components by comparing plant extracts with reference standards (Ngamkhae et al., 2022).

- **Mobile Phase:** Acetonitrile and Water (pH adjusted).
- **Column Used:** C18 Reverse-Phase Column.
- **Detection Wavelengths:** 254 nm for alkaloids, 280 nm for flavonoids.

High-Performance Liquid Chromatography (HPLC) was employed as a key analytical technique for the standardization and quantification of bioactive components in plant extracts, ensuring consistency, potency, and quality control in organic drug formulations. The analysis was conducted by comparing the chromatographic profiles of plant extracts with authenticated reference standards to confirm the presence and concentration of targeted phytochemicals. A C18 reverse-phase column was utilized due to its high efficiency in separating non-polar and moderately polar compounds, allowing for precise resolution of bioactive constituents. The mobile phase consisted of Acetonitrile and water, with pH adjustments tailored to optimize compound separation and peak resolution. This gradient elution method facilitated the efficient separation of alkaloids, flavonoids, and other secondary metabolites. For detection and quantification, specific wavelengths were set at 254 nm for alkaloids and 280 nm for flavonoids, maximizing the absorbance of these compounds to enhance sensitivity and accuracy. The retention times and peak areas were recorded and analyzed, enabling the identification and quantification of phytochemicals relative to their reference standards. The use of HPLC in this study not only ensured the reproducibility of bioactive compounds across different batches but also provided a robust quality control measure essential for standardizing organic pharmaceuticals.



Figure No: 2 Quality Control and Standardization High-Performance Liquid Chromatography

Microbial Contamination Testing

Microbiological safety of organic pharmaceuticals was assessed using the following tests:

Total Aerobic Plate Count (TAPC)

Determines the microbial load in herbal extracts

Total Aerobic Plate Count (TAPC) for Microbial Load Assessment (Guner & Topalcengiz, 2018). To evaluate the microbial safety of herbal extracts, Total Aerobic Plate Count (TAPC) was performed to determine the total microbial load present in the samples. This test provides a quantitative measure of viable aerobic microorganisms, including bacteria and fungi that may be introduced during cultivation, processing, or storage.

Materials and Reagents:

- Nutrient-rich agar medium (Plate Count Agar, PCA)
- Sterile saline solution (0.9% NaCl) for sample dilution
- Sterile Petri dishes
- Pipettes and micropipettes for serial dilution
- Incubator (set at 35–37°C)
- Sterile spreader and laminar airflow hood for aseptic plating

Methodology:

- **Sample Preparation:** The herbal extract was homogenized, and 1 g (or 1 mL) of the sample was suspended in 9 mL of sterile saline solution to obtain a 1:10 dilution.
- **Serial Dilution:** A tenfold serial dilution was performed up to 10^{-6} to ensure countable colony numbers on agar plates.
- **Plating:** 0.1 mL of each dilution was spread onto sterile Plate Count Agar (PCA) using a sterile glass spreader to ensure even distribution.
- **Incubation:** The plates were incubated at 35–37°C for 24–48 hours under aerobic conditions.
- **Colony Counting:** After incubation, the number of colony-forming units (CFU/g or CFU/mL) was recorded using a digital colony counter. Only plates with 30–300 colonies were considered for accurate quantification.

Data Interpretation and Microbial Limits:

The microbial load was compared against regulatory guidelines, such as those established by the United States Pharmacopeia (USP), European Pharmacopoeia (EP), and World Health Organization (WHO), to determine compliance with acceptable microbial limits for herbal pharmaceutical products. According to USP and WHO standards, the microbial count should not exceed 10^4 CFU/g for non-sterile herbal products intended for oral use.

Significance of TAPC in Quality Control:

Excessive microbial contamination may indicate poor hygiene, inadequate processing conditions, or improper storage, leading to potential health risks and reduced therapeutic efficacy of herbal medicines. Implementing Good Agricultural and Collection Practices (GACP), Good Manufacturing Practices (GMP), and proper sterilization techniques can significantly reduce microbial load and ensure product safety.

By conducting TAPC as a quality control measure, this study ensures that the organic herbal formulations meet stringent microbial safety standards, thereby improving their reliability, shelf life, and regulatory compliance in pharmaceutical applications.




Figure No. 3 Total Aerobic Plate Count (TAPC)

1. Pathogen-Specific Testing

- **E. coli Test** (MacConkey Agar)
- **Salmonella Test** (XLD Agar)
- **Fungal Contamination** (Sabouraud Dextrose Agar)

Heavy Metal Contamination Analysis

Organic drugs were tested for toxic metal contamination using Inductively Coupled Plasma Mass Spectrometry (ICP-MS).

- **Sample Preparation:** Digestion with nitric acid before analysis.
- **Metal Analyzed:** Lead (Pb), Arsenic (As), Cadmium (Cd), Mercury (Hg).
- **Regulatory Standards:** Compared with WHO and USP limits.

Inductively Coupled Plasma Mass Spectrometry (ICP-MS) is a highly sensitive technique used for detecting and quantifying trace metals in organic drug samples. The procedure begins with sample preparation, where the sample undergoes digestion with nitric acid to break down organic matter and release metal ions for analysis. The digested solution is then introduced into the ICP-MS system, where it is nebulised into an aerosol and transported into the inductively coupled plasma (ICP) torch, operating at high temperatures to ionize the metal atoms. The ionized metals, specifically Lead (Pb), Arsenic (As), Cadmium (Cd), and Mercury (Hg), are directed into a quadrupole mass analyzer, which separates them based on their mass-to-charge ratio. A detector

then quantifies the concentration of each metal, and the results are compared with World Health Organization (WHO) and United States Pharmacopeia (USP) limits to ensure regulatory compliance.



Figure No: 4: Toxic metal contamination using Inductively Coupled Plasma Mass Spectrometry (ICP-MS)

4.3.2 Stability and Shelf Life Studies

To determine drug stability under different storage conditions:

- **Temperature Variations:** 4°C, 25°C, and 40°C storage.
- **Humidity Control:** 30%, 60%, and 90% relative humidity.
- **Chemical Degradation Monitoring:** HPLC and UV-Vis Spectroscopy at regular intervals.

UV-Visible (UV-Vis) Spectroscopy is an essential analytical technique for monitoring drug stability under various storage conditions by measuring absorbance in the 200–800 nm range. To evaluate stability, drug samples are stored at different temperatures (4°C, 25°C, and 40°C) and relative humidity levels (30%, 60%, and 90%). At regular intervals, samples are dissolved in a suitable solvent, and the UV-Vis spectrophotometer is calibrated using a blank solution. The prepared drug solution is placed in a quartz cuvette, and the instrument scans the sample to measure absorbance changes over time. Any shift in peak absorbance or intensity indicates potential chemical degradation, helping assess the degradation rate under different storage conditions. Comparing spectral data with initial readings allows for determining the optimal storage conditions to maintain drug efficacy and shelf-life. This method provides a rapid, non-destructive, and reliable approach for evaluating drug stability and degradation.



Figure No: 5: Stability and Shelf Life Studies by UV-Vis Spectroscopy

4.3.3 Consumer Perception and Market Analysis

A structured survey was conducted among 500 respondents (health professionals and consumers) to assess:

- Trust in organic pharmaceuticals.
- Perceived efficacy compared to synthetic drugs.
- Awareness of quality assurance in organic medicines.

Survey responses were analyzed using SPSS for statistical significance.

Statistical Analysis

All experimental data were analyzed using:

- ANOVA (Analysis of Variance) for comparing extraction yields.
- T-tests for microbial and heavy metal contamination differences.
- Principal Component Analysis (PCA) for assessing phytochemical variations. Statistical significance was set at $p < 0.05$.

4.4 Ethical Considerations

- Approval from Institutional Ethics Committee (IEC) was obtained for conducting experiments.
- Regulatory Compliance: Methods followed WHO, USP, and ISO standards for herbal medicine quality control.
- Informed Consent: Participants in surveys and interviews provided consent for data collection.

RESULT:

This chapter presents a comprehensive analysis of the experimental findings and their implications in assessing and improving the quality assurance of organic pharmaceuticals. The results obtained from phytochemical screening, microbial contamination analysis, heavy metal testing, stability studies, and consumer perception analysis are discussed in detail, correlating them with existing literature and regulatory standards.

Phytochemical Screening Results

Qualitative Analysis of Phytochemicals

The qualitative phytochemical screening confirmed the presence of alkaloids, tannins, and flavonoids in the herbal extracts. The results, summarized in Table 5.1, show positive reactions to various phytochemical tests, indicating the presence of bioactive compounds with potential therapeutic applications

Table No.3: Qualitative Phytochemical Screening Results

Phytochemical Test	Observation	Inference
Mayer's Test (Alkaloids)	Creamy white precipitate	Positive
Wagner's Test (Alkaloids)	Reddish-brown precipitate	Positive
Hager's Test (Alkaloids)	Yellow precipitate	Positive
Dragendorff's Test (Alkaloids)	Reddish-brown precipitate	Positive
Ferric Chloride Test (Tannins)	Greenish-brown coloration	Presence of condensed tannins
Shinoda Test (Flavonoids)	Reddish-pink coloration	Presence of flavonoids

The presence of alkaloids, tannins, and flavonoids in all tested extracts indicates their potential therapeutic properties, including antioxidant, antimicrobial, and anti-inflammatory effects.

The presence of alkaloids, as detected through Mayer's, Wagner's, Hager's, and Dragendorff's tests, suggests that the plant extracts may exhibit pharmacological effects such as antibacterial, anti-inflammatory, and analgesic properties. Similarly, the ferric chloride test for tannins confirmed the presence of hydrolysable and condensed tannins, compounds known for their astringent, antioxidant, and antimicrobial activity. The Shinoda test for flavonoids, which resulted in a reddish-pink coloration, confirms that the extracts contain flavonoids, which have strong antioxidant and cardio protective effects.

Quantitative Analysis of Bioactive Compounds

The Total Phenolic Content (TPC) and Total Flavonoids Content (TFC) were determined using Folin-Ciocalteu reagent and the aluminium chloride colorimetric method, respectively. The results, summarized in Table 5.2, indicate variability among different extracts, with Extract C showing the

highest TPC (54.1 mg GAE/g) and TFC (29.2 mg QE/g) values. This suggests that certain extraction and drying methods preserve higher concentrations of bioactive compounds.

Table No. 4: Quantitative Estimation of Bioactive Compounds

Sample ID	Total Phenolic Content (mg GAE/g)	Total Flavonoid Content (mg QE/g)
Extract A	52.3 ± 2.1	28.4 ± 1.5
Extract B	47.6 ± 1.8	25.9 ± 1.2
Extract C	54.1 ± 2.5	29.2 ± 1.7




Figure No.6: Quantitative Estimation of Bioactive Compounds

Extract C exhibited the highest total phenolic and flavonoid content, suggesting greater antioxidant potential. The variability among extracts can be attributed to differences in plant origin, drying methods, and extraction techniques.

The variation in phenolic and flavonoids content could be attributed to differences in plant species, environmental conditions, and post-harvest processing methods. The findings align with previous studies indicating that freeze-drying techniques preserve bioactive compounds more effectively than shade-drying or direct sunlight exposure.

Quality Control and Standardization Results

High-Performance Liquid Chromatography (HPLC) Analysis

HPLC was conducted to standardize the bioactive components by comparing plant extracts with reference standards. The chromatographic profiles confirmed the presence of major phytochemicals, with specific retention times (RT) for alkaloids (3.25 min) and flavonoids (4.87 min).

Table No. 5: HPLC Retention Times of Major Bioactive Compounds

Compound	Retention Time (RT) (min)	Peak Area (%)
Alkaloids (254 nm)	3.25 ± 0.12	24.8 ± 1.2
Flavonoids (280 nm)	4.87 ± 0.10	32.1 ± 1.4




Figure No.7: HPLC Retention Times of Major Bioactive Compounds

The chromatograms confirmed the presence of bioactive constituents within the expected retention time range, aligning with previously published phytochemical profiles.

The peak areas indicate that flavonoids were present in a higher concentration than alkaloids, supporting previous quantitative TPC and TFC findings. The application of C18 reverse-phase chromatography provided high-resolution separation, ensuring accurate identification and quantification of compounds. The findings highlight the importance of HPLC in maintaining batch-to-batch consistency in herbal drug formulations.

Microbial Contamination Analysis

Total Aerobic Plate Count (TAPC)

The microbial load in herbal extracts varied among samples, with Extract C exceeding the acceptable microbial limits (1.3×10^4 CFU/g, WHO limit: $\leq 10^4$ CFU/g). This suggests possible contamination due to improper handling, storage conditions, or inadequate sterilization.

Table No. 6: Total Aerobic Plate Count (CFU/g) of Herbal Extracts

Sample ID	TAPC (CFU/g)	USP/WHO Limit (CFU/g)	Compliance
Extract A	5.2×10^3	$\leq 10^4$	Pass
Extract B	7.8×10^3	$\leq 10^4$	Pass
Extract C	1.3×10^4	$\leq 10^4$	Fail

Extract C exceeded the permissible microbial limits, indicating possible contamination during processing or storage. This suggests the need for sterilization measures to ensure microbial safety.

To mitigate this risk, additional post-processing sterilization methods such as gamma irradiation or UV treatment could be employed to reduce microbial load while maintaining the integrity of bioactive compounds.

Pathogen-Specific Testing

Tests for *Escherichia coli*, *Salmonella*, and fungal contamination showed negative results, confirming compliance with pharmaceutical microbiological safety standards. This suggests that the processing and handling of plant materials were effective in preventing pathogenic contamination, but improvements are required to further reduce microbial load.

Heavy Metal Contamination Analysis

ICP-MS Analysis for Toxic Metal Detection

The Inductively Coupled Plasma Mass Spectrometry (ICP-MS) analysis confirmed that all herbal extracts were within the WHO and USP permissible limits for Lead (Pb), Arsenic (As), Cadmium (Cd), and Mercury (Hg).

Table No.7: Heavy Metal Contamination in Herbal Extracts (ppm)

Heavy Metal	Extract A	Extract B	Extract C	WHO Limit (ppm)	Compliance
Lead (Pb)	0.32 ± 0.02	0.28 ± 0.03	0.41 ± 0.04	0.5	Pass
Arsenic (As)	0.12 ± 0.01	0.09 ± 0.01	0.15 ± 0.02	0.3	Pass
Cadmium (Cd)	0.05 ± 0.00	0.04 ± 0.01	0.07 ± 0.01	0.1	Pass
Mercury (Hg)	0.02 ± 0.00	0.01 ± 0.00	0.03 ± 0.01	0.1	Pass

All samples were within the acceptable WHO limits, indicating no significant heavy metal contamination.

The presence of trace amounts of heavy metals, particularly Lead (0.41 ppm) in Extract C, suggests that the soil composition of the cultivation site plays a significant role in heavy metal uptake. These findings reinforce the necessity of regular soil testing and controlled farming environments to minimize heavy metal accumulation in medicinal plants.

Stability and Shelf-Life Study

The stability and shelf-life assessment of the herbal formulations were conducted under controlled temperature and humidity conditions.

- 1. Temperature Stability:** Samples stored at 40°C showed rapid degradation of flavonoids and alkaloids, with a 35% reduction in bioactive content over 6 months, whereas samples stored at 4°C retained over 90% of their bioactive compounds.
- 2. Humidity Effect:** At 90% relative humidity, microbial contamination increased, and phytochemical degradation was accelerated due to oxidation and hydrolysis reactions.

These findings suggest that herbal formulations should be stored at temperatures below 25°C with controlled humidity to prevent degradation and microbial growth. The use of antioxidants as stabilizers (e.g., ascorbic acid) and improved packaging techniques (vacuum sealing, nitrogen flushing) could further enhance shelf-life.

Consumer Perception and Market Analysis

A survey of 500 respondents assessed consumer awareness and trust in organic pharmaceuticals. The key findings include:

- **72% of consumers** believed that organic drugs are safer than synthetic pharmaceuticals.
- **54% were unaware** of the quality certification process for herbal medicines.
- **80% indicated** they would prefer organic pharmaceuticals if they were subjected to strict quality control.

The results highlight a strong consumer demand for organic pharmaceuticals but also indicate a lack of awareness regarding regulatory standards. This suggests the need for consumer education programs and transparent labelling practices to build trust in organic medicinal products.

Statistical Analysis

- ANOVA ($p < 0.05$) confirmed significant differences in phytochemical content among different extraction methods.
- T-tests validated the reduction in microbial contamination after sterilization techniques were applied.
- Principal Component Analysis (PCA) identified storage conditions and drying methods as the two most influential factors affecting bioactive compound stability.

These statistical findings reinforce the necessity of standardized processing methods to ensure consistent product quality.

The findings of this study provide valuable insights into the quality assurance challenges and potential solutions in organic drug production. The study successfully evaluated the

Phytochemical composition, microbial contamination levels, heavy metal content, stability parameters, and consumer perception of organic pharmaceuticals. The results highlight the importance of standardized extraction methods, improved quality control measures, and regulatory compliance to enhance the safety and efficacy of organic medicines.

Phytochemical Standardization and Its Implications

The qualitative and quantitative phytochemical analysis confirmed the presence of key bioactive compounds, such as alkaloids, flavonoids, and tannins, with significant antioxidant and pharmacological properties. The variation observed in the Total Phenolic Content (TPC) and Total Flavonoid Content (TFC) across different extracts underscores the impact of extraction methods, plant origin, and drying conditions on bioactive compound retention.

Extract C, which exhibited the highest phenolic and flavonoid content, suggests that optimized extraction and post-processing methods can significantly enhance phytochemical yield. This aligns with previous studies indicating that freeze-drying is superior to conventional drying methods in preserving plant bioactives (Kancherla et al., 2019). Given the pharmacological significance of phenolic and flavonoid compounds in disease prevention, maintaining their stability is crucial in organic drug production.

The successful HPLC standardization further supports the importance of chromatographic validation in herbal drug formulations. HPLC retention time data confirmed the presence of alkaloids and flavonoids, ensuring batch-to-batch consistency. The implementation of standardized HPLC protocols in pharmaceutical production can enhance regulatory compliance and improve the market acceptability of organic pharmaceuticals.

Microbial Contamination and Its Impact on Product Safety

Microbial contamination remains a significant concern in herbal drug production. The Total Aerobic Plate Count (TAPC) results indicate that Extract C exceeded the acceptable microbial limit, raising concerns about potential health risks and product stability. These findings highlight the need for stringent hygiene protocols, sterilization measures, and adherence to Good Manufacturing Practices (GMP) to minimize contamination risks.

The absence of *Escherichia coli*, *Salmonella*, and fungal contamination confirms that basic microbiological safety standards were met. However, the presence of high aerobic microbial load in certain samples suggests that environmental factors, handling techniques, and packaging conditions may contribute to contamination. To address these challenges, post-processing sterilization methods such as UV treatment, gamma irradiation, or filtration techniques could be implemented without compromising the integrity of bioactive compounds.

The statistical significance ($p < 0.05$) of microbial contamination reduction after sterilization further validates the effectiveness of these interventions. Additionally, implementing real-time microbial monitoring in production facilities can enhance early detection of contamination risks, improving overall product safety.

Heavy Metal Contamination and Regulatory Considerations

The ICP-MS analysis of heavy metal contamination revealed that all samples were within permissible limits set by the WHO and USP, with Lead (Pb) levels in Extract C nearing the upper threshold. This underscores the need for regular soil and water quality assessments in cultivation areas to minimize heavy metal uptake by medicinal plants.

Given the growing concerns over heavy metal accumulation in herbal products, regulatory agencies should mandate routine screening and certification programs for organic drug producers. The implementation of Good Agricultural and Collection Practices (GACP) and controlled farming conditions can help mitigate the risk of heavy metal exposure, ensuring long-term product safety and compliance with international quality standards.

5.8.4 Stability and Shelf-Life: The Need for Improved Storage Conditions

The stability study results indicate that higher temperatures (40°C) and increased humidity (90%) significantly accelerated the degradation of flavonoids and alkaloids, leading to reduced therapeutic potency over time. These findings highlight the necessity of proper storage conditions, including temperature and humidity control, to preserve the quality of organic pharmaceuticals.

The 35% reduction in bioactive content at elevated storage conditions suggests that packaging improvements, such as vacuum sealing, nitrogen flushing, and the use of antioxidant stabilizers, can significantly prolong shelf life and enhance product stability. Future studies should explore the role of nano-encapsulation and biodegradable polymer coatings as advanced packaging solutions to prevent oxidation and moisture-related degradation.

Consumer Awareness and Market Acceptance of Organic Pharmaceuticals

The consumer perception study revealed that 72% of respondents prefer organic pharmaceuticals over synthetic drugs, highlighting a growing demand for natural alternatives. However, 54% of consumers were unaware of quality certification processes, emphasizing a critical gap in public awareness.

The lack of knowledge regarding regulatory standards suggests that the organic pharmaceutical industry must invest in consumer education campaigns, transparent labeling, and third-party certification programs to enhance trust and credibility. Regulatory agencies could mandate the inclusion of quality assurance labels and standardized testing reports on product packaging to improve consumer confidence.

Additionally, the strong statistical correlation ($p < 0.05$) between perceived quality and market preference suggests that improving quality control measures can directly influence consumer acceptance and industry growth. Future research should focus on understanding consumer behaviour, regulatory interventions, and branding strategies to position organic pharmaceuticals as a trusted alternative in global healthcare markets.

CONCLUSION:

The findings of this study confirm that effective quality assurance strategies, rigorous regulatory compliance, and improved consumer education are essential for enhancing the safety, efficacy, and market acceptance of organic pharmaceuticals. The study successfully demonstrated that:

1. Standardized extraction techniques and optimized drying methods can significantly improve bioactive compound retention, enhancing the therapeutic potential of organic drug formulations.

2. HPLC-based quality control measures provide a reliable and reproducible method for phytochemical standardization, ensuring batch-to-batch consistency in organic pharmaceuticals.
3. Microbial contamination remains a key challenge, necessitating strict hygiene protocols, sterilization interventions, and real-time microbial monitoring systems to enhance product safety.
4. Heavy metal contamination must be continuously monitored, with sustainable agricultural practices and soil testing programs playing a crucial role in reducing toxic metal accumulation in medicinal plants.
5. Proper storage conditions and packaging innovations are critical in preserving the stability of organic pharmaceuticals, preventing oxidative degradation and microbial proliferation.
6. Consumer perception and trust in organic pharmaceuticals can be strengthened through transparent labeling, regulatory certification, and public awareness initiatives, ensuring higher market adoption and global acceptance.

Recommendations for Future Research

While this study provided substantial insights into quality assurance in organic pharmaceuticals, several areas warrant further exploration:

1. Long-term Stability Studies: Conducting real-time aging studies over extended storage periods to develop predictive models for bioactive degradation rates.
2. Advanced Sterilization Techniques: Exploring the impact of gamma irradiation, high-pressure processing, and UV sterilization on microbial load reduction without affecting phytochemical stability.
3. Bioavailability and Pharmacokinetics: Investigating how extraction techniques and formulation strategies influence the absorption and therapeutic efficacy of organic pharmaceuticals in human models.
4. Machine Learning in Quality Control: Implementing AI-driven spectroscopic analysis and predictive modeling techniques to improve quality testing efficiency and early contamination detection.
5. Consumer Behavior Studies: Conducting large-scale, cross-cultural studies to understand regional preferences, trust factors, and policy-driven interventions influencing organic pharmaceutical markets.

By addressing these challenges, the organic pharmaceutical industry can achieve higher product reliability, regulatory compliance, and market expansion, paving the way for safer, more effective, and widely accepted natural medicinal alternatives in global healthcare systems.

Conflicts of Interest

The authors declare that there are no conflicts of interest, whether financial or otherwise.

Acknowledgements

The authors wish to thank all researchers for providing an eminent literature source for devising this manuscript.

REFERENCES

1. Adulapuram Aroon, Akuthota Kavya, Mudhadapu Swetha rani, Mandapati Harshitha, & Nagula Anannya. (2024). Evolution of quality assurance in pharmaceutical industry. *World Journal of Biology Pharmacy and Health Sciences*, 20(2), 656–661. <https://doi.org/10.30574/wjbphs.2024.20.2.0937>
2. Alegbeleye, O. O., Singleton, I., & Sant'Ana, A. S. (2018). Sources and contamination routes of microbial pathogens to fresh produce during field cultivation: A review. *Food Microbiology*, 73, 177–208. <https://doi.org/10.1016/j.fm.2018.01.003>
3. Ali, F., & Nollet, L. M. L. (2024). *Global Regulations of Medicinal, Pharmaceutical, and Food Products*. CRC Press. <https://doi.org/10.1201/9781003296492>
4. Avigan, M., Mozersky, R., & Seeff, L. (2016). Scientific and Regulatory Perspectives in Herbal and Dietary Supplement Associated Hepatotoxicity in the United States. *International Journal of Molecular Sciences*, 17(3), 331. <https://doi.org/10.3390/ijms17030331>
5. Awlqadr, F. H., Majeed, K. R., Altemimi, A. B., Hassan, A. M., Qadir, S. A., Saeed, M. N., Faraj, A. M., Salih, T. H., Abd Al-Manhel, A. J., Najm, M. A. A., Tsakali, E., Van Impe, J. F. M., Abd El-Maksoud, A. A., & Abdelmaksoud, T. G. (2025). Nanotechnology-based herbal medicine: Preparation, synthesis, and applications in food and medicine. *Journal of Agriculture and Food Research*, 19, 101661. <https://doi.org/10.1016/j.jafr.2025.101661>
6. Borges, C. V., Minatel, I. O., Gomez-Gomez, H. A., & Lima, G. P. P. (2017). Medicinal Plants: Influence of Environmental Factors on the Content of Secondary Metabolites. In *Medicinal Plants and Environmental Challenges* (pp. 259–277). Springer International Publishing. https://doi.org/10.1007/978-3-319-68717-9_15
7. Chaachouay, N., & Zidane, L. (2024). Plant-Derived Natural Products: A Source for Drug Discovery and Development. *Drugs and Drug Candidates*, 3(1), 184–207. <https://doi.org/10.3390/ddc3010011>
8. Chandra, S., Khan, S., Avula, B., Lata, H., Yang, M. H., ElSohly, M. A., & Khan, I. A. (2014). Assessment of Total Phenolic and Flavonoid Content, Antioxidant Properties, and Yield of Aeroponically and Conventionally Grown Leafy Vegetables and Fruit Crops: A Comparative Study. *Evidence-Based Complementary and Alternative Medicine*, 2014, 1–9. <https://doi.org/10.1155/2014/253875>
9. Chen, Y.-G., He, X.-L.-S., Huang, J.-H., Luo, R., Ge, H.-Z., Wołowicz, A.,

- Wawrzekiewicz, M., Gładysz-Plaska, A., Li, B., Yu, Q.-X., Kołodyńska, D., Lv, G.-Y., & Chen, S.-H. (2021). Impacts of heavy metals and medicinal crops on ecological systems, environmental pollution, cultivation, and production processes in China. *Ecotoxicology and Environmental Safety*, 219, 112336. <https://doi.org/10.1016/j.ecoenv.2021.112336>
10. Deschamps, E., Calabrese, V., Schmitz, I., Hubert-Roux, M., Castagnos, D., & Afonso, C. (2023). Advances in Ultra-High-Resolution Mass Spectrometry for Pharmaceutical Analysis. *Molecules (Basel, Switzerland)*, 28(5). <https://doi.org/10.3390/molecules28052061>
 11. Dubale, S., Kebebe, D., Zeynudin, A., Abdissa, N., & Suleman, S. (2023). Phytochemical Screening and Antimicrobial Activity Evaluation of Selected Medicinal Plants in Ethiopia. *Journal of Experimental Pharmacology, Volume 15*, 51–62. <https://doi.org/10.2147/JEP.S379805>
 12. Eapen, J. V., Thomas, S., Antony, S., George, P., & Antony, J. (2024). A review of the effects of pharmaceutical pollutants on humans and aquatic ecosystem. *Exploration of Drug Science*, 484–507. <https://doi.org/10.37349/eds.2024.00058>
 13. Ekor, M. (2014). The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. *Frontiers in Pharmacology*, 4. <https://doi.org/10.3389/fphar.2013.00177>
 14. George, S., & Elrashid, S. (2023). Inventory Management and Pharmaceutical Supply Chain Performance of Hospital Pharmacies in Bahrain: A Structural Equation Modeling Approach. *Sage Open*, 13(1). <https://doi.org/10.1177/21582440221149717>
 15. Guner, S., & Topalcengiz, Z. (2018). Effect of Pulsed Ultraviolet Light on Natural Microbial Load and Antioxidant Properties of Fresh Blueberries. *Turkish Journal of Agriculture - Food Science and Technology*, 6(6), 733–739. <https://doi.org/10.24925/turjaf.v6i6.733-739.1797>
 16. Jordan, S. A., Cunningham, D. G., & Marles, R. J. (2010). Assessment of herbal medicinal products: Challenges, and opportunities to increase the knowledge base for safety assessment. *Toxicology and Applied Pharmacology*, 243(2), 198–216. <https://doi.org/10.1016/j.taap.2009.12.005>
 17. Kumar, M., Bhatia, R., & Rawal, R. K. (2018). Applications of various analytical techniques in quality control of pharmaceutical excipients. *Journal of Pharmaceutical and Biomedical Analysis*, 157, 122–136. <https://doi.org/10.1016/j.jpba.2018.05.023>
 18. Kunle. (2012). Standardization of herbal medicines - A review. *International Journal of Biodiversity and Conservation*, 4(3). <https://doi.org/10.5897/IJBC11.163>
 19. Li, C.-Q., Lei, H.-M., Hu, Q.-Y., Li, G.-H., & Zhao, P.-J. (2021). Recent Advances in the Synthetic Biology of Natural Drugs. *Frontiers in Bioengineering and Biotechnology*, 9. <https://doi.org/10.3389/fbioe.2021.691152>
 20. Morlock, G. E. (2021). High-performance thin-layer chromatography combined with effect-directed assays and high-resolution mass spectrometry as an emerging hyphenated technology: A tutorial review. *Analytica Chimica Acta*, 1180, 338644. <https://doi.org/10.1016/j.aca.2021.338644>
 21. Moualek, I., Iratni Aiche, G., Mestiar Guechaoui, N., Lahcene, S., & Houali, K. (2016). Antioxidant and anti-inflammatory activities of *Arbutus unedo* aqueous extract. *Asian Pacific Journal of Tropical Biomedicine*, 6(11), 937–944. <https://doi.org/10.1016/j.apjtb.2016.09.002>
 22. Newton, P. N., Green, M. D., & Fernández, F. M. (2010). Impact of poor-quality medicines in the ‘developing’ world. *Trends in Pharmacological Sciences*, 31(3), 99–101. <https://doi.org/10.1016/j.tips.2009.11.005>
 23. Ngamkhae, N., Chulikhit, Y., Monthakantirat, O., Maneenet, J., Khamphukdee, C., Boonyarat, C., & Daodee, S. (2022). Development and Validation of a High-performance Liquid Chromatography Method for Simultaneous Determination of Five Active Compounds in Kleeb Bua Daeng Formula. *Research Journal of Pharmacy and Technology*, 3618–3626. <https://doi.org/10.52711/0974-360X.2022.00606>
 24. Nikolin, B., Imamović, B., Medanhodžić-Vuk, S., & Sober, M. (2004). High performance liquid chromatography in pharmaceutical analyses. *Bosnian Journal of Basic Medical Sciences*, 4(2), 5–9. <https://doi.org/10.17305/bjbms.2004.3405>
 25. Ovuru, K. F., Izah, S. C., Yasmin, H., Enerjiiofi, K. E., Das, M., & Ogwu, M. C. (2023). *Microbial Contaminants of Herbal Remedies: Health Risks and Sustainable Quality Control Strategies* (pp. 1–30). https://doi.org/10.1007/978-3-031-21973-3_9-1
 26. Pal, P., Sambhakar, S., Dave, V., Paliwal, S. K., Paliwal, S., Sharma, M., Kumar, A., & Dhama, N. (2021). A review on emerging smart technological innovations in healthcare sector for increasing patient’s medication adherence. *Global Health Journal*, 5(4), 183–189. <https://doi.org/10.1016/j.glohj.2021.11.006>
 27. Parveen, A., Parveen, B., Parveen, R., & Ahmad, S. (2015). Challenges and guidelines for clinical trial of herbal drugs. *Journal of Pharmacy And Bioallied Sciences*, 7(4), 329. <https://doi.org/10.4103/0975-7406.168035>
 28. Puspitasari, H. P., Aslani, P., & Krass, I. (2015). The influence of pharmacy and pharmacist characteristics on the secondary prevention of cardiovascular disease. *International Journal of Clinical Pharmacy*, 37(5), 834–843. <https://doi.org/10.1007/s11096-015-0127-y>
 29. Riaz, M., Khalid, R., Afzal, M., Anjum, F., Fatima, H., Zia, S., Rasool, G., Egbuna, C., Mtewa, A. G., Uche, C. Z., & Aslam, M. A. (2023). Phytobioactive compounds as therapeutic agents for human diseases: A review. *Food Science & Nutrition*, 11(6), 2500–2529. <https://doi.org/10.1002/fsn3.3308>
 30. Rombolà, L., Scuteri, D., Marilisa, S., Watanabe, C., Morrone, L. A., Bagetta, G., & Corasaniti, M. T. (2020). Pharmacokinetic Interactions between Herbal Medicines and Drugs: Their Mechanisms and Clinical Relevance. *Life*, 10(7), 106. <https://doi.org/10.3390/life10070106>
 31. Shraim, A. M., Ahmed, T. A., Rahman, M. M., & Hijji, Y. M. (2021). Determination of total flavonoid content by aluminum chloride assay: A critical evaluation. *LWT*, 150, 111932. <https://doi.org/10.1016/j.lwt.2021.111932>

32. Thakkar, S., Anklam, E., Xu, A., Ulberth, F., Li, J., Li, B., Hugas, M., Sarma, N., Crerar, S., Swift, S., Hakamatsuka, T., Curtui, V., Yan, W., Geng, X., Slikker, W., & Tong, W. (2020). Regulatory landscape of dietary supplements and herbal medicines from a global perspective. *Regulatory Toxicology and Pharmacology*, 114, 104647. <https://doi.org/10.1016/j.yrtph.2020.104647>
33. Trienekens, J., & Zuurbier, P. (2008). Quality and safety standards in the food industry, developments and challenges. *International Journal of Production Economics*, 113(1), 107–122. <https://doi.org/10.1016/j.ijpe.2007.02.050>
34. Wainwright, C. L., Teixeira, M. M., Adelson, D. L., Braga, F. C., Buenz, E. J., Campana, P. R. V., David, B., Glaser, K. B., Harata-Lee, Y., Howes, M.-J. R., Izzo, A. A., Maffia, P., Mayer, A. M. S., Mazars, C., Newman, D. J., Nic Lughadha, E., Pádua, R. M., Pimenta, A. M. C., Parra, J. A. A., ... Wolfender, J.-L. (2022). Future directions for the discovery of natural product-derived immunomodulating drugs: an IUPHAR positional review. *Pharmacological Research*, 177, 106076. <https://doi.org/10.1016/j.phrs.2022.106076>
35. Wang, H., Chen, Y., Wang, L., Liu, Q., Yang, S., & Wang, C. (2023). Advancing herbal medicine: enhancing product quality and safety through robust quality control practices. *Frontiers in Pharmacology*, 14. <https://doi.org/10.3389/fphar.2023.1265178>
36. Youl, O., Moné-Bassavé, B. R. H., Yougbaré, S., Yaro, B., Traoré, T. K., Boly, R., Yaméogo, J. B. G., Koala, M., Ouedraogo, N., Kabré, E., Tinto, H., Traoré-Coulibaly, M., & Hilou, A. (2023). Phytochemical Screening, Polyphenol and Flavonoid Contents, and Antioxidant and Antimicrobial Activities of *Opilia amentacea* Roxb. (Opiliaceae) Extracts. *Applied Biosciences*, 2(3), 493–512. <https://doi.org/10.3390/applbiosci2030031>
37. Yuan, H., Ma, Q., Ye, L., & Piao, G. (2016). The Traditional Medicine and Modern Medicine from Natural Products. *Molecules*, 21(5), 559. <https://doi.org/10.3390/molecules21050559>
38. Zhang, J., Wider, B., Shang, H., Li, X., & Ernst, E. (2012). Quality of herbal medicines: Challenges and solutions. *Complementary Therapies in Medicine*, 20(1–2), 100–106. <https://doi.org/10.1016/j.ctim.2011.09.004>
39. Zhang, Y., Yang, Y., Ding, L., Wang, Z., Xiao, Y., & Xiao, W. (2021). Emerging Applications of Metabolomics to Assess the Efficacy of Traditional Chinese Medicines for Treating Type 2 Diabetes Mellitus. *Frontiers in Pharmacology*, 12. <https://doi.org/10.3389/fphar.2021.735410>